Covid-19 drugs among top-selling brands for pharma players in India

Data shows that cumulative sales of remdesivir was Rs 510 crore in January 2021, while for favipiravir it was Rs 471 crore

Covid-19 drugs such as remdesivir and favipiravir now feature among the top selling pharma brands in the country. 

Within months of their launch in 2020, these drugs emerged in the top club, competing with long-selling cardiac, respiratory and other key brands for the pharma companies. 

The data from market research firm AIOCD Pharmasofttech AWACS (AIOCD AWACS) shows that the cumulative sales of remdesivir was Rs 510 crore in January; for favipiravir, it was Rs 471 crore. 

In a matter of months, favipiravir (FabiFlu), an oral antiviral drug used to treat mild to moderate Covid, has become the No. 1 brand for Glenmark Pharmaceuticals